AGWCA
BTAI

Annis Gardner Whiting Capital Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-156
Closed -$210 – 462
2026
Q1 		$210 Buy
156
+44
+39% +$72 ﹤0.01% 1270
2025
Q4 		$180 Buy
+112
New +$231 ﹤0.01% 1175

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's BTAI Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of BioXcel Therapeutics (BTAI) in Q2 2026, closing a stake of 156 shares — an estimated $210 sold.

Annis Gardner Whiting Capital Advisors first reported a position in BTAI in Q4 2025 and held it in 2 quarters. The position peaked at $210 in Q1 2026. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining BioXcel Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 156 BioXcel Therapeutics shares in Q2 2026, an estimated $210.
  • Annis Gardner Whiting Capital Advisors first reported a position in BioXcel Therapeutics in Q4 2025 and held it in 2 quarters.
  • Annis Gardner Whiting Capital Advisors's BioXcel Therapeutics position peaked at $210 in Q1 2026.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.